Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin…
October 05, 2025 09:00 ET | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…
Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE…